A phase II, open‐label evaluation of cysteamine tolerability in patients with Huntington's disease

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 2, 2015-02 ,pp. : 288-289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 1, 2018-01 ,pp. : 69-77

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’’s disease in children: REACH open-label extension

By Hyams Jeffrey   Walters Thomas D.   Crandall Wallace   Kugathasan Subra   Griffiths Anne   Blank Marion   Johanns Jewel   Lang Yinghua   Markowitz James   Cohen Stanley   Winter Harland S.   Veereman-Wauters Gigi   Ferry George   Baldassano Robert  

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 651-662

Informa Healthcare

Access to resources Recommend Favorite

High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 25, Iss. 1, 2018-01 ,pp. : 120-127

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy

By Sakka Paraskevi   Tsolaki Magda   Hort Jakub   Hager Klaus   Soininen Hilkka   López Pousa Secundino   Li Chunming   Schwam Elias  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3153-3165

Informa Healthcare

Access to resources Recommend Favorite